Japanese regulations and JSQA update. Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016

Size: px
Start display at page:

Download "Japanese regulations and JSQA update. Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016"

Transcription

1 Japanese regulations and JSQA update Tadahiro Yoshiyama International Affairs Committee Director of GLP Division November 11, 2016

2 Contents Japanese regulatory updates of the GxP systems Recent activities in JSQA Expectations of new collaborations between RQA and JSQA International Affairs Committee / JSQA 11/11/2016 2

3 Japanese regulatory updates of the GxP systems International Affairs Committee / JSQA 11/11/2016 3

4 Summary Over the past year, a partial revision and expansion of the evaluation scope occurred in the Japanese GxP systems The inspection methods and perspectives of the Japanese regulatory authority may be changed International Affairs Committee / JSQA 11/11/2016 4

5 Expansion of the GLP evaluation scope 1. Coming into effect in GLP ordinance for cellular and tissue based products Ministerial Ordinance on Good Laboratory Practice for Non Clinical Safety Studies of Cellular and Tissue Based Products (Ordinance of the Ministry of Health and Welfare No. 88 of July 30, 2014) 2. Start of the facility inspection by PMDA and inspection of 8 facilities has already been carried out JSQA started collection and analysis of the information about the inspection by PMDA in GLP subcommittee 5 International Affairs Committee / JSQA 11/11/2016

6 Coming into effect in New OECD Advisory Document on GLP computerized system OECD SERIES ON PRINCIPLES OF GOOD LABORATORY PRACTICE AND COMPLIANCE MONITORING Number 17 Impact in the CSV activity in Japan Responsibility of the Facility Management newly recognized Scope Validation activity of the appropriate frequency according to a risk assessment results Personnel Life Cycle Importance of the participation of Study director, IT person and system vendor Periodic Review Securing of quality of Electric Record& Signature System Inventory Validation strategy based on potential risks to data integrity Risk Assessment Up-to-date listing of all GLP-relevant systems International Affairs Committee / JSQA 6

7 Japanese Compassionate Use (J-CU) has begun at last Japanese Good Clinical Practice (J-GCP) was partially revised this year, because the inclusion of J-CU. the partial revision of J-GCP for Drugs MHLW Ministerial Ordinance No.9 became effective from Jan 22, the partial revision of J-GCP for Medical Devices MHLW Ministerial Ordinance No.128 became effective from Jul 21, the partial revision of J-GCP for Regenerative Medicines MHLW Ministerial Ordinance No.129 became effective from Jul 21, J-CU applications 3 protocols were published. (As of 30 Sep., 2016) International Affairs Committee / JSQA 11/11/2016 7

8 Revision of the recent GVP-related law Revision of the Pharmaceutical Affairs Law (November 27, 2013) GVP-related laws were revised(july 30, 2014) Summery of Revision GVP ordinance Cellular and tissue based products were increased as an object of post-marketing safety management operations Pharmaceutical Affairs Law Enforcement Regulation About the entrustment of post-marketing safety management operations, Re-entrustment was accepted, under the constant condition 8 International Affairs Committee / JSQA 11/11/2016

9 Recent GVP In-compliances In one company, advance reaction was not reported within the period by system failure. Medicinal Product : 5475 cases (57 ingredients) Investigational Products: 154 cases (28 ingredients) Correspondence of the MHLW To One company which violated Business Suspension Order :15 days Business Improvement Order : Twice To Representatives of first-class Pharmaceutical marketing authorization holders (271 Companies) Requested to do Voluntary Self-Inspection about the inhouse GVP systems Result In 20 companies, the defects of the procedure were found out In 6 companies, Advance reaction information unreported (88 cases in total 133 examples)

10 Recent activities in JSQA Making of medium and long term administration policies, covering the next 5 years International Affairs Committee / JSQA 11/11/

11 Making of medium and long term administration policies and schedules JSQA set the policies and plans for our activities in line with the change in environment Structure of Members (As of 31 Aug., 2016) 1366 members from 426 companies GQP/GVP/GPSP Division 15% GLP Division 37% GCP Division 48% GLP Division: 496 members from 155 companies GCP Division: 662 members from 187 companies GQP/GVP/GPSP Division: 208 members from 84 companies International Affairs Committee / JSQA 11/11/

12 Making of medium and long term administration policies and schedules Policies and schedules aim at getting the following results in five years Announcement of the outcome of the selected study Publication of the activity result by methods such as a presentation at the meeting or the article contribution. Collection of outside evaluations about activities and referring them to the next problem setting meeting. Completion of the educational training system & establishment of the QA authorization Establishment of the QA authorization in each GxP system. International Affairs Committee / JSQA 11/11/

13 Making of medium and long term administration policies and schedules Policies and schedules aim at getting the following results in five years The strengthening of the liaison between external/internal related associations and regulatory authorities Collaboration with external/internal related associates and regulatory authorities. Further cooperation between RQA, SQA and JSQA, about 5 th and 6 th GQAC. Arrangement of operations and systems, leading to activation Increase the number of members engaged in the GQP/GMP/ GDP, Medical device or QMS. International Affairs Committee / JSQA 11/11/

14 Expectations of new collaborations between RQA and JSQA International Affairs Committee / JSQA 11/11/

15 Effective use of collaborations JSQA is expecting further collaborations with RQA, on various topics The making of deliverables through collaborations The employment of RQA training materials for JSQA personnel The holding of periodical meetings about an discussion items International Affairs Committee / JSQA 11/11/

16 Autumn Scenes in Japan JSQA will support the 5th GQAC.So, through cooperation and information sharing, let's make this event a success. 11/11/20 International Affairs Committee / JSQA 16 16

17 Effective use of collaborations The deliverables which come from the material of the collaboration. Activity Summary of 12th Term( ) - GLP Division - GCP Division - GQP/GVP/GPSP Division - Common Special Project 1, 2 Activity Summary of 11th Term( ) - GLP Division - GCP Division - Common Special Project 1, /11/ International Affairs Committee / JSQA

18 Thank you ありがとうございました International Affairs Committee / JSQA 11/11/

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS Post-marketing surveillance (PMS) to assure the quality, efficacy and safety of drugs after they go on the market and to establish proper methods of use of

More information

Indian Pharmacopoeia Commission

Indian Pharmacopoeia Commission Indian Pharmacopoeia Commission JP 130 th Anniversary Symposium Tokyo, Japan 15 th Sept, 2016 Dr.G.N.Singh Secretary cum Scientific Director, Overview Indian Pharmaceutical Industry Pharmacopoeia and NFI

More information

Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan

Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan 1 5 th Joint Conference of Taiwan and Japan on Medical Products Regulation Overview of Generic Drug Policy and Introduction of its Review Points/BE Guideline in Japan Mr. Yoshihiko Sano Deputy Director,

More information

Reports of Adverse Drug Reactions, etc. of Pharmaceuticals

Reports of Adverse Drug Reactions, etc. of Pharmaceuticals (Attachment) Reports of Adverse Drug Reactions, etc. of Pharmaceuticals 1 GLOSSARY (1) Drugs, quasi-drugs, and cosmetics -1- Related to Article 228-20, paragraph 1, item 1 of the Enforcement Ordinance

More information

GLP Update and Hot Topics

GLP Update and Hot Topics GLP Update and Hot Topics RQA Annual Conference Mark Goodwin 9 Nov 2016 Introduction International GLP Updates OECD including MAD Agreement EC/ EMA US FDA & US EPA UK GLP Update MHRA MHRA GLP Deficiencies

More information

Ms. Wajihah Binti Haji Zainuddin Halal Food Control Division, MoRA. Brunei Seminar & Showcase ASEAN-Japan Hall February 25, 2014

Ms. Wajihah Binti Haji Zainuddin Halal Food Control Division, MoRA. Brunei Seminar & Showcase ASEAN-Japan Hall February 25, 2014 Ms. Wajihah Binti Haji Zainuddin Halal Food Control Division, MoRA Brunei Seminar & Showcase ASEAN-Japan Hall February 25, 2014 1 Presentation Overview Halal Certifying Body Procedure of Halal Certification

More information

Agenda. The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Pharmaceutical Excipients

Agenda. The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Pharmaceutical Excipients The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Dr. Keiji Kijima, Secretary General, IPEC Japan April 26, 2012 Agenda JPE (Japanese ) JP (Japanese Pharmacopoeia)

More information

Points to Consider CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan

Points to Consider CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan 2013 CPhI Japan Briefing Session on Pharmaceutical Regulations in Japan The Master File System and Points to Consider Kentaro Hashimoto, Master File Management Group, Division of Pharmacopoeia and Standards

More information

Regulatory Systems of Health Claims in Japan. June, 2011 Consumer Affairs Agency Food Labelling Division

Regulatory Systems of Health Claims in Japan. June, 2011 Consumer Affairs Agency Food Labelling Division Regulatory Systems of Health Claims in Japan June, 2011 Consumer Affairs Agency Food Labelling Division Mission of the Consumer Affairs Agency (CAA) Article 2 of the Consumer Basic Act sets out the state

More information

On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents

On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents Administrative Notice 1 July 9, 2010 To: Pharmaceutical Affairs Divisions, Prefectural Public Health Bureaus (Departments) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau,

More information

Welcome to Celerion s Dinner and Discussion Program Tokyo, Japan Apr 2, 2015

Welcome to Celerion s Dinner and Discussion Program Tokyo, Japan Apr 2, 2015 Welcome to Celerion s Dinner and Discussion Program Tokyo, Japan Apr 2, 2015 Fast to Patient: The Push For Earlier Signals of Efficacy in Clinical Research J. Fred Pritchard, Ph.D. Vice President, Global

More information

Yui Matsuda, PhD, RN, MPH, YunKyung Chang, PhD, RN, Todd Schwartz, DrPH & Linda S. Beeber, PhD, RN, CS, FAAN

Yui Matsuda, PhD, RN, MPH, YunKyung Chang, PhD, RN, Todd Schwartz, DrPH & Linda S. Beeber, PhD, RN, CS, FAAN Associations among maternal depressive symptoms, maternal diathesis factors and family characteristics in families with young children having developmental delay or disability Yui Matsuda, PhD, RN, MPH,

More information

Test Article Analyses in Compliance with Good Laboratory Practice in Japan: Circumstances and Changes

Test Article Analyses in Compliance with Good Laboratory Practice in Japan: Circumstances and Changes Test Article Analyses in Compliance with Good Laboratory Practice in Japan: Circumstances and Changes Harumi Namiki 1, *, Tetsuya Shigeta 2, Yoshitaka Ino 3, Kanzo Kimura 4, Katsutoshi Inaba 5, Sachio

More information

The use of the CTQA model also holds promise for easier identification of opportunities for improvement by enabling the clarification of metrics and K

The use of the CTQA model also holds promise for easier identification of opportunities for improvement by enabling the clarification of metrics and K Study Group Study Group 1: QMS Subgroup C-1-A Construction of a Quality Assurance System for Clinical Trials Subgroup A, Study Group 1 (hereinafter, this group) worked on the following tasks based on the

More information

Singapore s Progress on GLP and MAD

Singapore s Progress on GLP and MAD 2010/SOM1/CD/WKSP/025 Agenda Item: Afternoon Session I Singapore s Progress on GLP and MAD Submitted by: Singapore Case Study Workshop on the Chemicals Sector - From Principles to Practice Hiroshima, Japan

More information

- Notification to specify uniform limit (Ministry of Health, Labour and Welfare Notification No. 497, 2005)

- Notification to specify uniform limit (Ministry of Health, Labour and Welfare Notification No. 497, 2005) Syoku-An No.1129001 November 29, 2005 *1 Director Notice *2 Department of Food Safety Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare Establishment of Applicable Laws and Ordinances

More information

Standard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes

Standard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP

More information

AQPWBRoyhbThSIjE: :42:34 : 1XCrl6 vjcbuwhpahpe, [url= Cartridges, device kits, power options.

AQPWBRoyhbThSIjE: :42:34 : 1XCrl6 vjcbuwhpahpe, [url=  Cartridges, device kits, power options. corp@stantec.com Latest Press Release chrome has been freezing S Thought Of The Day. ADVERTISEMENT Get the latest news and analysis in the stock market today, including national and world stock market

More information

Program to Promote Use of Generic Drugs in Japan

Program to Promote Use of Generic Drugs in Japan Program to Promote Use of Generic Drugs in Japan March 22, 2012 CPhI Japan 2012 Tsuyoshi Matsuno Economic Affairs Division, Health Policy Bureau, Ministry of Health, Labour and Welfare * A Japanese translation

More information

How does economic deprivation lead to problem drinking?

How does economic deprivation lead to problem drinking? The 6 th Doshisha - Chung-Ang University Joint Seminar on East Asian Social Welfare How does economic deprivation lead to problem drinking? : The mediating effect of income inequality consciousness and

More information

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the

More information

PMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA

PMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA 15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight PMDA Perspectives

More information

1 2 3 Based on the contents detailed below, assess the substantial equivalence to a legally marketed predicate device. In that case, the standards, et

1 2 3 Based on the contents detailed below, assess the substantial equivalence to a legally marketed predicate device. In that case, the standards, et Attachment 8 Application for Treatment Positive Airway Pressure Unit, etc. (1) Scope of application Continuous positive airway pressure units and Continuous-automated positive airway pressure units in

More information

Nattha Kerdsakundee,Ph.D. Regional Manager Department of International Trials

Nattha Kerdsakundee,Ph.D. Regional Manager Department of International Trials Nattha Kerdsakundee,Ph.D. Regional Manager Department of International Trials Disclaimer These Power Point slides are the intellectual property of NCGM under the copyright laws. Used by permission. All

More information

Heng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare

Heng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare Heng-Jung Lien Section Chief Division of Medicinal Products, Food and Drug Administration, Ministry of Health and Welfare, Taiwan, R.O.C. 衛生福利部食品藥物管理署 Food and Drug Administration, Ministry of Health and

More information

Surgery of the spleen and liver an introduction Liver Fossum chapter 21. Liver diagnostics. Liver diagnostics

Surgery of the spleen and liver an introduction Liver Fossum chapter 21. Liver diagnostics. Liver diagnostics Surgery of the spleen and liver an introduction 2017 11 30 Liver Fossum chapter 21 For diagnostics Biopsy of the liver! Portosystemic shunts the principle The Gallbladder disease and treatment Always biopsy

More information

MHRA Pharmacovigilance Inspections: Prepare and Manage for Success

MHRA Pharmacovigilance Inspections: Prepare and Manage for Success MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage

More information

Director-General, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare

Director-General, Department of Food Safety, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Notice No. 0315 Article 1 of the Department of Food Safety March 15, 2012 To: All the Prefectural Governors All the Mayors in Cities with Public Health Centers All the Mayors of Special Wards Director-General,

More information

GLOBAL BIOANALYSIS CONSORTIUM

GLOBAL BIOANALYSIS CONSORTIUM GLOBAL BIOANALYSIS CONSORTIUM Scope and Regulations Harmonization Team: A1 (Work in Progress) John Smeraglia on behalf of the HT-A1 A1: Scope and regulations Team members: Team lead Region Expertise Surendra

More information

Why Do You Study? Complex Answers to a Simple Question. Mimi Bong. Department of Education Brain & Motivation Research Institute Korea University

Why Do You Study? Complex Answers to a Simple Question. Mimi Bong. Department of Education Brain & Motivation Research Institute Korea University Why Do You Study? Complex Answers to a Simple Question Mimi Bong Department of Education Brain & Motivation Research Institute Korea University 1 interest self-efficacy volition Self-defeating ego goals

More information

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

Basic guidelines for promotion of control measures for hepatitis

Basic guidelines for promotion of control measures for hepatitis Basic guidelines for promotion of control measures for hepatitis May 16, 2011 Table of Contents Chapter 1 Basic approach for preventing hepatitis and promoting medical care of hepatitis - 2 - Chapter 2

More information

Clinical trial consultation system (utility and successful cases from company s point of view)

Clinical trial consultation system (utility and successful cases from company s point of view) Clinical trial consultation system (utility and successful cases from company s point of view) 3 rd China-Japan Symposium on Drug Development March 22, 2012 Japan Pharmaceutical Manufacturers Association

More information

STAFF REPORT City of Lancaster NB 2

STAFF REPORT City of Lancaster NB 2 STAFF REPORT City of Lancaster NB 2 12/13/16 MVB Date: December 13, 2016 To: From: Subject: Mayor Parris and City Council Members Mark V. Bozigian, City Manager Allison E. Burns, City Attorney Ordinance

More information

Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient

Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Adaptive and Innovative Study Designs to Accelerate Drug Development from First-In-Human to First-In-Patient Michelle L. Combs, PhD Vice President, Clinical Pharmacology Sciences New Drug And Biologics

More information

(Tentative Translation)

(Tentative Translation) (Tentative Translation) Public Notice of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Health, Labour and Welfare (MHLW) No. 2 of December 17, 2010 Table

More information

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6

More information

TERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY

TERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY TERMS AND CONDITIONS OF NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY FOR OBTAINING AND MAINTAINING ITS GLP CERTIFICATION BY A TEST FACILITY Document No.GLP-101 Version/Issue

More information

National Strategies for Controlling Avian Influenza Viruses

National Strategies for Controlling Avian Influenza Viruses National Strategies for Controlling Avian Influenza Viruses Viet Nam Background information Animal population Major animal diseases of concerns Population of Livestock in Viet Nam Year Buffalo Cattle Pigs

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL

More information

Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York

Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York Ken Whittemore, Jr. R.Ph., MBA Senior VP, Professional & Regulatory Affairs Copyright Copyright 2015 by 2015 Surescripts,

More information

Mitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective

Mitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective Mitigation of risk and selection of clinical starting dose a PMDA nonclinical perspective Mineo Matsumoto DVM, PhD, DJST Office of New Drug Ⅱ Pharmaceutical and Medical Devices Agency Disclaimers The views

More information

Quality of Clinical Trials -PMDA s Point of View-

Quality of Clinical Trials -PMDA s Point of View- Quality of Clinical Trials -PMDA s Point of View- Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author

More information

Government structure on Food safety and Animal health system in Japan

Government structure on Food safety and Animal health system in Japan Government structure on Food safety and Animal health system in Japan Japan-EU EPA Negotiation Round 4 SPS group meeting 28-29 January, 2014 Food Safety & Consumer Affairs Bureau Ministry of Agriculture,

More information

The Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods

The Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods The Second Draft of Provisional Maximum Residue Limits (MRLs) for Agricultural Chemicals in Foods The Ministry of Health, Labour and Welfare revised Food Sanitation Law in May 2003. Based on the revised

More information

Committed to Environment, Health, & Safety

Committed to Environment, Health, & Safety Committed to Environment, Health, & Safety Environment, Health, and Safety Management System and Policy of W. R. Grace & Co. November 8, 2018 The Grace Environment, Health, and Safety Management System,

More information

EPA REGULATORY UPDATE

EPA REGULATORY UPDATE SOCIETY OF QUALITY ASSURANCE REGULATORY FORUM EPA REGULATORY UPDATE Linthicum Heights, Maryland January 24, 2008 Robert Cypher United States Environmental Protection Agency 2/13/2008 SQA Baltimore 1 ANY

More information

Update on JP-TW OTC drugs WG

Update on JP-TW OTC drugs WG Update on JP-TW OTC drugs WG Fumihito Takanashi Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labor and Welfare (MHLW) 7, December,

More information

The Danish Medicines Agency s availability strategy

The Danish Medicines Agency s availability strategy låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images

More information

Ensuring the gap between science and practice is filled safely - MHRA

Ensuring the gap between science and practice is filled safely - MHRA Safeguarding public health Ensuring the gap between science and practice is filled safely - MHRA Diane Leakey Head of Information and Communications, MHRA April 2012 Agenda Who is MHRA? Why we have regulation?

More information

Use of TTC and Human Relevance George E. N. Kass, PhD

Use of TTC and Human Relevance George E. N. Kass, PhD Use of TTC and Human Relevance George E. N. Kass, PhD Future Challenges in Developing Assessment Methodologies for Human Health Effects Tokyo, 14 November 2018 Disclaimer The views, thoughts and opinions

More information

Chapter Coordinator Guide

Chapter Coordinator Guide Congratulations becoming an ILA Chapter Coordinator! An ILA chapter coordinator plays a vital role in supporting his or her chapter as the group works together to improve literacy for all. ILA s Board

More information

Announcement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines Act (AMG)

Announcement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines Act (AMG) Federal Gazette No 127 dated 24 August 2011, p. 2975-2977 Federal Ministry of Health Announcement regarding the publication of the results of clinical trials in accordance with Section 42b of the Medicines

More information

Medical Cannabis Uses

Medical Cannabis Uses Medical Cannabis Uses Comprehensive Ordinance Cannabis Policy Subcommittee February 16, 2017 David Guhin, Director Clare Hartman, Deputy Director-Planning Planning and Economic Development 1 City Response

More information

Quality Assurance Policy. for the. Procurement of HIV Point-of-Care Technology. under the UNITAID Grant

Quality Assurance Policy. for the. Procurement of HIV Point-of-Care Technology. under the UNITAID Grant Quality Assurance Policy for the Procurement of HIV Point-of-Care Technology under the UNITAID Grant UNICEF Supply Division Quality Assurance Centre and Health Technology Centre Revisions Version Date

More information

City of Santa Rosa Comprehensive Cannabis Policy

City of Santa Rosa Comprehensive Cannabis Policy City of Santa Rosa Comprehensive Cannabis Policy Council Policy Subcommittee September 12, 2017 David Guhin, Director Clare Hartman, Deputy Director - Planning Planning and Economic Development 1 Santa

More information

Kazuhiko Mori Ministry of Health, Labour and Welfare

Kazuhiko Mori Ministry of Health, Labour and Welfare Kazuhiko Mori Ministry of Health, Labour and Welfare 1 1. The Establishment of the Japanese Pharmacopoeia 2. Revisions of the Japanese Pharmacopoeia and Changes in Pharmaceutical Regulation 3. Current

More information

POLICY ON DRUGS & ABUSE

POLICY ON DRUGS & ABUSE POLICY ON DRUGS & ABUSE 1 Statement of Need Nangia & Co has a strong commitment to the health, safety and welfare of its employees, their families and its customers. Widely available statistics and information

More information

Environment, Health and Safety Management System. Management of Contractors Procedure

Environment, Health and Safety Management System. Management of Contractors Procedure Environment, Health and Safety Management System Procedure Revision History Revision No. Review Date 1.0 Feb/2018 Description of Change Replacing the Health & Safety Sr. Officer with Health & Safety Specialist/

More information

Calendar of Events. 1 2 June 2006 RAPS 2006 European Conference: EU Regulatory Response to Innovation and Global Competitiveness

Calendar of Events. 1 2 June 2006 RAPS 2006 European Conference: EU Regulatory Response to Innovation and Global Competitiveness Calendar of Events 31 May 2 June 2006 The Validation Manager Venue: Vienna, Austria. 1 2 June 2006 RAPS 2006 European Conference: EU Regulatory Response to Innovation and Global Competitiveness Venue:

More information

THE GOVERNMENT DECREES: Chapter I GENERAL PROVISIONS

THE GOVERNMENT DECREES: Chapter I GENERAL PROVISIONS GOVERNMENT S DECREE No. 108/2007/ND-CP OF JUNE 26, 2007, DETAILING THE IMPLEMENTATION OF A NUMBER OF ARTICLES OF THE LAW ON HIV/AIDS PREVENTION AND CONTROL THE GOVERNMENT Pursuant to the December 25, 2001

More information

Update from FDA Office of Regulatory Affairs

Update from FDA Office of Regulatory Affairs Update from FDA Office of Regulatory Affairs Ellen F. Morrison Assistant Commissioner for Medical Products and Tobacco Operations Office of Regulatory Affairs U.S. Food and Drug Administration 1 The Impact

More information

34th SQA Annual Meeting

34th SQA Annual Meeting 34th SQA Annual Meeting Registration Brochure www.sqa.org/sqa2018-1 - The Wonderful World of Quality The Society of Quality Assurance invites you to Anaheim, California for the 34th SQA Annual Meeting

More information

Review Report. (11) Olanzapine Fine Granules 1% "DSEP" (14) Olanzapine OD Tablets 10 mg "DSEP" (17) Olanzapine Tablets 10 mg "Nichi-Iko"

Review Report. (11) Olanzapine Fine Granules 1% DSEP (14) Olanzapine OD Tablets 10 mg DSEP (17) Olanzapine Tablets 10 mg Nichi-Iko Review Report November 13, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical products submitted for marketing approval conducted

More information

Cutanea Life Sciences, Inc. Comprehensive Compliance Program

Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea engages in research, development, manufacture and marketing of dermatology products, including commercialization of those products.

More information

Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy)

Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy) Individualised Treatment Planning for Radionuclide therapy (Molecular Radiotherapy) FMU/ICRP workshop 2017 Glenn Flux Royal Marsden Hospital & Institute of Cancer Research Sutton UK ICRP Task Group 101

More information

Controlled Substances Program. For Academic Units

Controlled Substances Program. For Academic Units Brigham Young University Page 1 Provo, Utah Controlled Substances Program For Academic Units Last Revised: November 30, 2009 Brigham Young University Page 2 TABLE OF CONTENTS Section Title Page 1.0 Overview

More information

BJA Performance Measures

BJA Performance Measures BJA Performance Measures Timothy J. Willis, Ph.D. Senior Research Associate, CSR, Inc. timothy.willis@ojp.usdoj.gov (202) 514-8045 At the end of this session you will be able to: 1. Explain the value of

More information

The Role of the Responsible Pharmacist (RP)

The Role of the Responsible Pharmacist (RP) The Role of the Responsible Pharmacist (RP) Pharmaceutical industry perspective Vuyo Mokoena: Senior Manager: Monitoring, Compliance and Professional Conduct (MCPC) Overview Background Legislative provision

More information

Organ Donation from Brain-Dead Donors and the Role of the Japan Organ Transplant Network

Organ Donation from Brain-Dead Donors and the Role of the Japan Organ Transplant Network Research and Reviews Organ Donation from Brain-Dead Donors and the Role of the Japan Organ Transplant Network JMAJ 54(6): 357 362, 2011 Atsushi AIKAWA* 1 Abstract The Japan Organ Transplant Network (JOT)

More information

Guidance on Drug Master File System in Japan

Guidance on Drug Master File System in Japan 2 nd China Japan Symposium on Drug Development focusing on IND, Pre Consultation, ti GMP and DMF System March 29, 2011 in Beijing Guidance on Drug Master File System in Japan Takashi YOSHITANI, Ph.D. Master

More information

BIENNIAL REVIEW Compliance with the Drug-Free Schools and Communities Act. St. Johns River State College

BIENNIAL REVIEW Compliance with the Drug-Free Schools and Communities Act. St. Johns River State College BIENNIAL REVIEW Compliance with the Drug-Free Schools and Communities Act St. Johns River State College 2016-2018 The Drug-Free Schools and Communities Act of 1989, Public Law 101-226, requires that St.

More information

Best Practices in FDA 483 and Warning Letter Management and Recovery

Best Practices in FDA 483 and Warning Letter Management and Recovery Best Practices in FDA 483 and Warning Letter Management and Recovery Elaine C. Messa, RAC Director, Medical Device Quality Systems and Compliance Practice This document is intended to facilitate an oral

More information

Cooperation between HALMED and GMP Inspectorate in supervision of manufacturers: Croatia s experience so far

Cooperation between HALMED and GMP Inspectorate in supervision of manufacturers: Croatia s experience so far Cooperation between HALMED and GMP Inspectorate in supervision of manufacturers: Croatia s experience so far Ana Boban, MPharm. Agency for Medicinal Product and Medical Devices of Croatia Dubrovnik, 06.05.2013.

More information

Update FDA/Center for Food Safety and Applied Nutrition

Update FDA/Center for Food Safety and Applied Nutrition Update FDA/Center for Food Safety and Applied Nutrition Comments by Susan Mayne, Ph.D. Director Center for Food Safety and Applied Nutrition FDLI Annual Conference May 3, 2018 Food Safety, Nutrition and

More information

Comparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome

Comparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome Comparability and quality of experimental data under different quality systems S. Caroli Istituto Superiore di Sanità Rome Programme of this presentation Part I. Background information Part II. Key aspects

More information

Recommendations for Regulators Cannabis Operations

Recommendations for Regulators Cannabis Operations Recommendations for Regulators Cannabis Operations Developed by: Cannabis Committee American Herbal Products Association 8630 Fenton Street, Suite 918 Silver Spring, MD 20910 www.ahpa.org This document

More information

Changes to the Eighth Edition

Changes to the Eighth Edition Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,

More information

Open Access MegaJournals

Open Access MegaJournals Open Access MegaJournals SPARC Japan Feb 2012 Leading a Transformation in Research Communication Peter Binfield Publisher, PLoS ONE pbinfield@plos.org @p_binfield The Public Library of Science An organization

More information

Committed to Environment, Health and Safety

Committed to Environment, Health and Safety Committed to Environment, Health and Safety Environment, Health and Safety Management System and Policy of GCP Applied Technologies Inc. SEPTEMBER 1, 2017 The GCP Environment, Health, and Safety Management

More information

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria

More information

Standards of Conduct for Transmission Providers

Standards of Conduct for Transmission Providers Standards of Conduct for Transmission Providers Posted and Effective as of December 30, 2016 Puget Sound Energy ( PSE ) is a public utility that owns, operates, and controls facilities used for the transmission

More information

Policy of Conflict of Interest in Clinical Research

Policy of Conflict of Interest in Clinical Research Policy of Conflict of Interest in Clinical Research The Japan Society of Hepatology Academic-industrial collaboration has been assigned as a national strategy to assist in establishing Japan as a nation

More information

Need for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines

Need for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines Need for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines Patrick Zuber - WHO Meeting with vaccine manufacturers 5 April

More information

Division of Research University Policy

Division of Research University Policy Division of Research University Policy SUBJECT: Effective Date: Policy Number: SATELLITE ANIMAL HOUSING FACILITIES June 24, 2016 Supersedes: August 22, 2014 1 5 Responsible Authorities: Vice President,

More information

European Medicines Enforcement Network

European Medicines Enforcement Network Safeguarding public health European Medicines Enforcement Network 14 th ICDRA, Singapore December 2010 Nimo Ahmed Head of Intelligence Medicines and Healthcare products Regulatory Agency Outline MHRA Enforcement

More information

Increase Hepatitis B Screening and Vaccinations

Increase Hepatitis B Screening and Vaccinations 17 Increase Hepatitis B Screening and Vaccinations Situation Viral hepatitis is considered to be the most common contagious disease in Japan. Of the estimated three million patients and carriers of viral

More information

CDER Compliance Update

CDER Compliance Update CDER Compliance Update Donald D. Ashley, JD 22 nd Annual GMP by the Sea August 30, 2017 www.fda.gov www.fda.gov 2 Office of Compliance Structure Office of Compliance Office of Drug Security, Integrity

More information

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices

Regulatory Framework for Medical Devices in South Africa. 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Regulatory Framework for Medical Devices in South Africa 23 November 2018 Andrea Keyter Deputy Director: Medical Devices Medicines and Related Substances Act, 1965 (Act 101 of 1965) Act 72 of 2008 and

More information

PFC Industry Courses and Certifications

PFC Industry Courses and Certifications PFC Industry Courses and Certifications Americans for Safe Access (ASA) has been a trusted source of cannabis education and training for over 15 years. As a leader in medical cannabis education since 2002,

More information

REGULATIONS IN FOOD INGREDIENTS

REGULATIONS IN FOOD INGREDIENTS REGULATIONS IN FOOD INGREDIENTS Prepared by: CPL Business Consultants The Manor House, Howbery Park, Wallingford, Oxfordshire, OX10 8BA Tel: +44 1491 822 844, info@cplconsult.com, www.cplconsult.com Catherine

More information

Regulatory scientific significance of Japan s ADR relief system

Regulatory scientific significance of Japan s ADR relief system Regulatory scientific significance of Japan s ADR relief system Toshi TOMINGA, Ph.D. Associate Executive Director Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed

More information

720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013

720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013 Conflict of Interest Declaration Compounding at a Crossroads: The Federal and State Outlook Christopher J. Topoleski has no actual or potential conflicts of interest in relation to this activity Christopher

More information

Quality, Safety and Sourcing in Unlicensed Medicines

Quality, Safety and Sourcing in Unlicensed Medicines Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?

More information

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014 Good Laboratory Practice EU-Serbia screening meeting Brussels, 19 June 2014 Table of contents 1. Background information on the principles of GLP 2. EU legal basis for GLP 3. Role of Member States 4. Role

More information

Merced, California Next Steps and Strategies for Successful Implementation of Cannabis-Related Health and Safety Regulations

Merced, California Next Steps and Strategies for Successful Implementation of Cannabis-Related Health and Safety Regulations Merced, California Next Steps and Strategies for Successful Implementation of Cannabis-Related Health and Safety Regulations Presented by: Neil Hall Arcelia Herrera May 9, 2017 4745 Mangels Blvd, Fairfield,

More information

POLICIES & PROCEDURES

POLICIES & PROCEDURES Policy Name: Page 1 of 7 I. POLICY Evidence-based clinical research regarding influenza has shown that the best method for prevention and control of seasonal influenza is vaccination. The purpose of this

More information

NIGERIAN EXPERIENCE OF THE BIOLOGICAL AND TOXIN WEAPONS CONVENTION

NIGERIAN EXPERIENCE OF THE BIOLOGICAL AND TOXIN WEAPONS CONVENTION MEETING OF THE STATES PARTIES TO THE CONVENTION ON THE PROHIBITION OF THE DEVELOPMENT, PRODUCTION AND STOCKPILING OF BACTERIOLOGICAL (BIOLOGICAL) AND TOXIN WEAPONS AND ON THEIR DESTRUCTION BWC/MSP/2007/WP.8

More information

Rite aid employment verification

Rite aid employment verification Rite aid employment verification Information, reviews and commentary for Rite Aid Offices located at 30 Hunter Lane, Camp Hill, PA, 17011. support team, advancement opportunities at every level and training

More information